The United States Food and Drug Administration (FDA) has released the\nlatest investigation results regarding a botulism outbreak in infants,\nwhich was previously linked to the ByHeart and Nara Organics infant\nformula brands. Authorities discovered the presence of Clostridium\nbotulinum bacteria in one of the powdered milk raw ingredients, but have\nnot yet been able to confirm the primary source triggering the\noutbreak.<\/p>\n
Botulism is a rare disease that can be fatal as it attacks the\nnervous system. The disease is caused by toxins produced by the\nClostridium botulinum bacteria, which can trigger muscle paralysis and\nlead to respiratory failure.<\/p>\n
The FDA noted that the outbreak, which lasted from late 2025 to early\n2026, was officially declared over on 26 February 2026. During this\nperiod, 48 infants across 17 US states were reported to be infected.<\/p>\n
During the investigation process, the FDA conducted direct\ninspections of ByHeart\u2019s production facilities and one of its raw\nmaterial suppliers.<\/p>\n
This investigation was launched after FDA inspection reports from\n2023 resurfaced during the outbreak. At that time, the FDA found several\nviolations related to food safety and hygiene at one of ByHeart\u2019s\nproduction facilities, which has since been closed. The company also\nreceived a warning letter from the FDA in the same year.<\/p>\n
However, based on the latest investigation, the FDA stated it found\nno evidence that those previous violations contributed to the botulism\noutbreak occurring in 2025-2026.<\/p>\n
Both the FDA and ByHeart did find the presence of Clostridium\nbotulinum in one of the powdered milk raw ingredients. Nevertheless, no\nother factors were found that could explain how this contamination\ncaused the outbreak.<\/p>\n
Contamination Found in Raw Ingredients<\/p>\n
The FDA also inspected Dairy Farmers of America, a milk processing\ncompany for Organic West Milk, which serves as one of ByHeart\u2019s\nsuppliers.<\/p>\n
Whole Genome Sequencing (WGS) analysis showed that the Clostridium\nbotulinum bacteria found in two samples from one batch of organic\npowdered milk was identical to the bacteria found in clinical samples\nfrom sick infants and in finished formula products that tested\npositive.<\/p>\n
Despite this, the FDA is continuing its root cause analysis,\nspecifically regarding the raw materials used in the production\nprocess.<\/p>\n
As a follow-up, ByHeart is developing an action plan to strengthen\nfood safety systems throughout its entire production process.<\/p>\n
The company will implement new testing methods for Clostridium\nbotulinum with higher sensitivity levels. These protocols are being\ndeveloped in collaboration with independent laboratories.<\/p>\n
Testing will subsequently be conducted on all raw milk ingredients as\nwell as every batch of finished products before they are brought to\nmarket.<\/p>\n
Additionally, ByHeart will expand its supplier audits, increase the\nfrequency of raw material testing, implement a QR code-based batch\ntracking system, and establish an independent Food Safety Advisory\nBoard.<\/p>\n
FDA Prepares Preventative Measures<\/p>\n
On the other hand, the FDA has also begun drafting various steps to\nprevent similar incidents from recurring.<\/p>\n
One such measure involves increasing surveillance sampling to\ndetermine how frequently Clostridium botulinum is found in powdered\nmilk.<\/p>\n
The agency is also working to deepen its understanding of the risks\nposed by this bacteria in infant formula and is developing best\npractices for the industry during the production process.<\/p>\n
The FDA is also encouraging the Joint FAO\/WHO Expert Meetings on\nMicrobiological Risk Assessment (JEMRA) to conduct a risk assessment of\nspore-forming bacteria, including Clostridium botulinum and Bacillus\ncereus, in powdered infant formula.<\/p>\n
Furthermore, the FDA supports the request from the Codex Committee on\nFood Hygiene for JEMRA to update risk assessments for Cronobacter and\nSalmonella in powdered infant formula, while also developing stricter\ncontrol recommendations spanning production, packaging, and the\npreparation of infant formula.<\/p>", "url": "https:\/\/jawawa.id\/newsitem\/two-infant-formulas-under-scrutiny-after-botulism-outbreak-latest-fda-findings-1782658273", "image": "" }, "sponsor": "Okusi Associates", "sponsor_url": "https:\/\/okusiassociates.com" }